Phio Commences Toxicology Study for PH-762, Advances Viable Product in 2026

Phio Pharmaceuticals has commenced a toxicology study for its lead siRNA compound, PH-762, which is being developed to silence the PD-1 gene in various forms of skin cancer. The company is also advancing initiatives to deliver a commercially viable product in 2026, funded by recent financing. Positive interim safety and efficacy results have been reported in the ongoing Phase 1b trial for PH-762.